Novartis Avidity Drug Fails in Third Trial Setback in a Week
9 Articles
9 Articles
Only a few days ago the pharmaceutical company Novartis had reported problems in the development of an important drug. Now the next setback follows. The stock reacts immediately.
Novartis (NVS) Stock Craters 12% After Three Drug Failures in One Week
TLDR Novartis fell over 12% on Tuesday, on track for its worst trading day since March 2020. Its del-desiran drug failed the Phase III HARBOR trial for myotonic dystrophy type 1, missing the primary endpoint. This marks the third drug trial setback for Novartis in a week, following the pelacarsen...
Novartis is taking a heavy hit on the markets, with its stock falling about 10% on Tuesday after another drug candidate failed in an advanced-stage clinical trial.… Novartis: 10% plunge after third clinical trial failure in a week - ΙΝΑΦΤΕΜΟΠΟΡΙΚΙ
Novartis shares plunged 10% on Tuesday (8/9) after the pharmaceutical giant announced that its drug del-desiran for a neuromuscular disorder that causes muscle wasting failed in a late-stage trial. More specifically, according to CNBC, the company's share price drop is essentially attributed to investor reactions after the third clinical trial failure of Novartis' drug in a week. In fact, it should be noted that the above development put the sto…
Coverage Details
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
